Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology Trial AB20/99)

European Urology

Volumn 60, Issue 5, 2011, Pages 1087-1096

  Niegisch, Günter ^a   Fimmers, Rolf ^b   Siener, Roswitha ^b   Park, Su In ^b   Albers, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Prognostic factors; Second line treatment; Urothelial cancer

Indexed keywords

CISPLATIN; GEMCITABINE; HEMOGLOBIN; PACLITAXEL; VINFLUNINE;

ACCURACY; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; URINARY TRACT CANCER; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; DEOXYCYTIDINE; FEMALE; GERMANY; HEMOGLOBINS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT SELECTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 81155160994     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.063     Document Type: Article

References (16)

1. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
2. C.N. Sternberg, P.H. de Mulder, and J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924 J Clin Oncol 19 2001 2638 2646 (Pubitemid 32441368)
3. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608 (Pubitemid 46224062)
4. J. Bellmunt, C. Theodore, and T. Demkov Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
5. P. Albers, S.I. Park, and G. Niegisch Randomized phase III trial of second line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Ann Oncol 22 2011 288 294
6. C.N. Sternberg, F. Calabro, G. Pizzocaro, L. Marini, S. Schnetzer, and A. Sella Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 92 2001 2993 2998 (Pubitemid 33136193)
7. G. Fechner, R. Siener, M. Reimann, L. Kobalz, and P. Albers Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99) Int J Clin Pract 60 2006 27 31 (Pubitemid 43732573)
8. J. Li, B. Juliar, and C. Yiannoutsos Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study J Clin Oncol 23 2005 1185 1191 (Pubitemid 46202275)
9. K. Kanai, E. Kikuchi, and T. Ohigashi Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy Int J Clin Oncol 13 2008 510 514
10. J. Bellmunt, T.K. Choueiri, and R. Fougeray Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 28 2010 1850 1855
11. C. Ma, S. Bandukwala, and D. Burman Interconversion of three measures of performance status: an empirical analysis Eur J Cancer 46 2010 3175 3183
12. O. Beahrs, D. Earl Henson, R. Hutter, and M. Myers American Joint Committee on Cancer, Purposes and principles of staging O. Beahrs, D. Earl Henson, R. Hutter, M. Myers, Manual for staging of cancer. 1988 J.B. Lippincott Philadelphia, PA 3 10
13. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
14. G. Sonpavde, J.E. Rosenberg, and N.M. Hahn Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma J Clin Oncol 28 2010 e205 e207 author reply e8
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. J. Lehmann, H. Suttmann, and P. Albers Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05) Eur Urol 55 2009 1293 1299